InflaRx to Unveil Key Vilobelimab Data for Rare Skin Disease

JENA, Germany – March 18, 2026 – Biopharmaceutical company InflaRx is poised to take center stage at a major dermatology conference, where it will present pivotal Phase 3 clinical trial data for its investigational drug, vilobelimab, as a potential treatment for the severe and rare skin disease pyoderma gangrenosum (PG).

The company announced today that its findings have been accepted for a late-breaking oral presentation at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado. The selection for a late-breaker session, a slot typically reserved for highly significant and timely research, has focused industry attention on the drug's potential for a condition that currently has no FDA-approved treatments.

The presentation, titled “Vilobelimab Treatment for Ulcerative Pyoderma Gangrenosum: Results from a Multicenter, Randomized, Placebo Controlled Phase 3 Trial,” is scheduled for March 28 and will be delivered by Dr. Benjamin Kaffenberger.

“It is an honor that our Phase 3 study data for vilobelimab in pyoderma gangrenosum (PG) have been selected for a late-breaking oral presentation at AAD,” said Dr. Camilla Chong, Chief Medical Officer of InflaRx, in a statement. “We look forward to engaging with the dermatology community on these critical findings in PG and our development program.”

The Devastating Impact of Pyoderma Gangrenosum

For those living with pyoderma gangrenosum, the need for an effective, targeted therapy is desperate. PG is a rare and painful neutrophilic dermatosis characterized by the rapid development of large, deep, and excruciatingly painful skin ulcers. These ulcers can appear spontaneously or after minor trauma, a phenomenon known as pathergy, which makes even simple wound care and surgical interventions fraught with risk.

The disease carries a heavy burden, significantly impairing quality of life and often leading to prolonged hospital stays, substantial healthcare costs, and high morbidity. Patients frequently struggle with chronic pain, disfigurement, and social isolation. The absence of any specifically approved therapies means clinicians must rely on a trial-and-error approach with off-label systemic treatments, primarily potent immunosuppressants like high-dose corticosteroids and cyclosporine.

While these drugs can be effective for some, they carry a significant risk of serious side effects. In recent years, biologic agents targeting inflammatory pathways, such as TNF-alpha inhibitors like infliximab, have been used with some success but are also not specifically approved for PG and may not work for all patients. This therapeutic gap leaves a significant unmet need for safer, more reliable, and targeted treatments.

Targeting the Engine of Inflammation

InflaRx's vilobelimab represents a highly targeted approach to quelling the inflammation that drives pyoderma gangrenosum. It is a first-in-class monoclonal antibody that works by inhibiting complement component C5a, a small but powerful protein in the body's immune system.

C5a acts as a potent inflammatory mediator, essentially serving as a powerful distress signal that recruits and activates neutrophils—the type of white blood cell that accumulates in PG ulcers and causes tissue damage. By selectively binding to and neutralizing free C5a, vilobelimab aims to cut off this key inflammatory signal at its source, thereby reducing neutrophil-driven inflammation without causing broad immunosuppression.

This mechanism is particularly relevant for PG, where the skin lesions are defined by an overabundance of activated neutrophils. Researchers have found that the receptors for C5a are highly expressed in PG lesions, suggesting that the C5a pathway is a critical driver of the disease. By targeting this specific pathway, InflaRx hopes to offer a more precise and potentially safer way to control the devastating effects of the condition.

A Complex but Hopeful Path Forward

The journey for vilobelimab in pyoderma gangrenosum has been complex. The Phase 3 trial was previously terminated early after an interim analysis concluded it was unlikely to meet its original primary endpoint: complete closure of the target ulcer on two consecutive visits. Such an outcome could have spelled the end of the program.

However, subsequent and more detailed post-hoc analyses of the data painted a different, more promising picture. While the stringent endpoint of complete closure was not met, the data revealed a statistically significant treatment effect in favor of vilobelimab for reducing the volume of the target ulcer. One analysis showed a 63.2% reduction in ulcer volume at Week 26 for patients on vilobelimab compared to placebo. Furthermore, patients treated with the drug reported significant improvements in their quality of life, as measured by the Dermatology Life Quality Index (DLQI).

“Focusing solely on complete ulcer closure can be a very high bar in a complex, chronic disease like PG,” commented one immunologist not involved with the study. “Seeing a significant and sustained reduction in ulcer volume is a clinically meaningful outcome. For a patient, a smaller, less painful ulcer that is clearly healing represents a major therapeutic victory, even if it hasn't closed completely.”

These nuanced findings are what InflaRx will present to the dermatology community. The favorable safety profile observed in the trial, with most adverse events being mild to moderate, further strengthens the case for the drug's potential role.

InflaRx's Broader Strategy in Inflammation

The upcoming AAD presentation is a crucial moment for InflaRx. A positive reception from the medical community could bolster the company's discussions with regulatory agencies like the FDA to define a viable path toward potential approval, a process the company has stated it may pursue with a strategic partner.

Success with vilobelimab would not only provide a desperately needed option for PG patients but also validate InflaRx's core scientific platform focused on C5a/C5aR inhibition. The company is leveraging this expertise across its pipeline, most notably with izicopan, an orally administered C5a receptor inhibitor currently in development for other debilitating inflammatory skin diseases like hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU).

As the pyoderma gangrenosum treatment market—estimated to be worth hundreds of millions of dollars annually—continues to grow, the race for the first approved therapy is on. While competitors are also exploring novel targets, InflaRx's late-breaking data on vilobelimab could position it as a serious contender, offering a glimmer of hope for patients and a potentially pivotal advance in the treatment of inflammatory diseases.